{"id":"NCT02281552","sponsor":"Pfizer","briefTitle":"A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-18","primaryCompletion":"2017-03-15","completion":"2017-03-15","firstPosted":"2014-11-03","resultsPosted":"2018-10-12","lastUpdate":"2018-10-12"},"enrollment":209,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]}],"arms":[{"label":"tofacitinib modified release tablet","type":"EXPERIMENTAL"},{"label":"tofacitinib immediate release tablet","type":"ACTIVE_COMPARATOR"}],"summary":"This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrexate. Results for the modified release tablets will be compared to the efficacy and safety of the 5 mg tofacitinib immediate release tablets taken twice a day in patients with rheumatoid arthritis who continue taking methotrexate.","primaryOutcome":{"measure":"Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Tofacitinib Modified Release (MR)","deltaMin":-2.43,"sd":0.09},{"arm":"Tofacitinib Immediate Release (IR)","deltaMin":-2.85,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":36,"countries":["Japan"]},"refs":{"pmids":["36931693","36601090","36600185","36526796","30137547"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921215&StudyName=A%20study%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20tofacitinib%20modified%20release%20tablets%20compared%20to%20tofacitinib%20immediate%20release%20tablets%20in"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":104},"commonTop":["Nasopharyngitis"]}}